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Spectral studiesAbstract Five novel compounds possessing hydrazinyl carbothioamide moiety were designed and
synthesized. All the compounds were tested for in vitro biological activities. Most of the tested com-
pounds displayed strong antibacterial and antifungal activities. Molecular docking studies sug-
gested that the hydrazinyl carbothioamide moiety of compounds (6–10) can in general be
accommodated the binding pocket of the breast cancer protein (1JNX) and are responsible for
the activity of the whole of the molecule. The docking results provide a new insight into the design
of hydrazinyl carbothioamide derivatives as breast cancer drug.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Bacterial and fungal infections are growing problem in con-
temporary medicine, as a result of the increasing use of anti-
bacterial agents for all kinds of infectious diseases on
mankind, many drug-resistant pathogens have appeared on
recent years besides that of various human diseases, cancer
has proved to be one of the most intractable diseases to which
human beings are subjected, and as yet no practical and
generally effective drugs or methods of control are available.Therefore, identiﬁcation of novel potent, selective and less
toxic anticancer agents remains one of the most pressing health
problems [1]. Hetero cycles possessing nitrogen and sulfur het-
ero atoms are found to exhibit a wide spectrum of biological
activities including antibacterial [2] and antifungal [3], activi-
ties. Many hydrazinyl carbothioamide containing compounds
are reported as herbicidal [4], fungicidal [5], anti-tubercular
[6], anti allergic [7], anti anaphylactic [8], antiarthritic [9], anti-
biotic [10], antiviral [11], anti-inﬂammatory [12], analgesic [13]
and psychotropic agents [14]. A series of hydrazine carbothioa-
mide derivatives were synthesized possessing excellent antibac-
terial and antifungal activities [15–17], they have also been
shown to possess antimalarial [18–20], antibiotic [21], antican-
cer [22], antiinﬂammatory [23], antihypertensive [24], tyrokin-
ase PDGF–RTK inhibition [25] and anti-HIV [26,27]
properties. The molecular docking technique [28,29], plays an
important role in the drug design and discovery to predict
the conformations of each ligand molecule at the active
site. So it was planned to synthesize new hydrazinyl
444 D. Chinnaraja, R. Rajalakshmicarbothioamide derivatives with 1, 4-disubstitution using a
green route that is microwave organic reaction enhancement
method (MORE) and test them for in vitro antifungal and anti-
bacterial activities. The rigid molecular docking studies of
newly synthesized hydrazinyl carbothioamide derivatives were
carried out to predict the antibacterial activity and molecular
docking are reported.
2. Results and discussion
2.1. Chemistry
In view of the large amount of literature that addresses
organic-TSCs and their applications as potential antineo-
plastic and antibacterial agent, it is surprising that aryl eth-
anone incorporated analogs with these biological targets
have not been extensively studied. So we determined to
design and synthesize a series of N-14, N-17-disubstituted
hydrazine carbothioamide derivatives (6–10) by the reaction
of 2-bromo-1-aryl ethanone either with substituted ketone/R2
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Scheme 1 Synthesis of hydrazinyl caldehyde or with thiosemicarbazide Scheme 1. The synthe-
sized compounds were characterized by (Preparation of
3-acetyl-2H-benzo[g]chromen-2-one), 1H NMR Spectrum of
compound 3 (Preparation of 3-acetyl-2H-benzo[g]chromen-
2-one) (Fig. S1), IR, 1H NMR, 13C NMR, 2D NMR
spectrum of 1H–13C COSY, HR-Mass spectrometry and
Elemental analysis. In the IR spectrum of compound 6
the peaks at 1656, 1601, 1315 and 3429 cm1 are due to
carbonyl and C‚O, C‚N C‚S and NH stretching
frequencies.
2.2. NMR spectral analysis
In the 1H NMR spectrum (Fig. S2) of compound 6 (Fig. 1)
there is a singlet observed at 9.30 ppm that should be due to
the coumarinyl benzylic proton (H-4). The (H-17a/b) protons
of (H-17) appeared as singlet at 4.71 ppm. The two singlets
appeared at 2.78 (methyl) and 3.89 (methoxy) each with three
protons integral value must be due to the methyl and methoxy
protons. The aromatic protons pertaining to the coumarinylCl
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arbothioamide derivatives (6–10).
Figure 1 (E)-N-(2-(4-methoxyphenyl)-2-oxoethyl)-2-(1-(2-oxo-
2H-benzo[g]chromen-3-yl)ethylidene)hydrazinyl carbothioamide.
Design and synthesis of hydrazinyl carbothioamide derivatives 445and phenyl rings are observed as doublet and triplet at around
6.96–8.36 ppm.
In the 13C NMR spectrum (Fig. S3) of the compound 6 the
C-12 carbon is observed around 164.8 ppm, while the C-16
carbon is resonating at around 189.2 ppm. The signals in the
region 195.6 ppm in compound 6 are the characteristics of
the C-19 carbon. The C-2 carbon is observed at 156.2 ppm.
The signal in the upﬁeld region 30.7 ppm is due to the methyl
carbon. The methylene carbon (C-17) of hydrazinyl carbo-
thioamide functions on the region 43.0 ppm. The compound
also possesses a signal at 55.7 ppm which is a characteristic
of the methoxy carbon.
The aromatic carbons appeared at around 112.2–
136.3 ppm. The ipso carbons of the phenyl ring and the
coumarinyl group show a characteristic absorption further
down ﬁeld region. In methoxy compound 6 the most down
ﬁeld signal is assigned to methoxy bearing ipso carbon
159.4 ppm. The above assignments are further conﬁrmed by
recording 1H–13C COSY spectrum for the representative
compound 6.
Using 1H–13C COSY spectrum (Fig. S4) of the representa-
tive compound 6 13C signals can be assigned without ambigu-
ity. The signal at 143.3 ppm has a cross peak with proton
signal pertaining to H-4. Hence the signal at 143.3 ppm should
be due to C-4. The signal at 116.5 ppm has a cross peak with
the signal at 7.45–7.47 ppm (8.0 Hz) corresponding to H-6 pro-
tons and the signal with chemical shift (116.5 ppm) is due to
C-6. The signal at 7.59–7.63 ppm (16.0 Hz) exhibits strong
cross peak with the triplet 7.59–7.63 ppm pertaining to H-8
and H-8g0. Therefore the signal at 126.7 ppm must be due to
C-8 and C-80 ppm. The signal at 129.8 ppm has cross peak
with the signals (triplet) in the region 7.73–7.76 (12.0 Hz)
and 7.89–7.93 ppm (16.0 Hz) pertaining to H-9 and H-20Table 1 Minimal inhibitory concentration (MIC, mg/mL) of hydra
Strains
Amikacin Amphotericin
S. typhi 25 -
S. aureus 50 -
E. coli 50 -
k.pneumoniae 50 -
Pseudomonas 25 -
A. ﬂavus - 50
C. albicans - 25
A. fumigatus - 25
A. niger - 25and H-200 protons. Hence the signal with chemical shift
129.8 ppm must be due to C-9 and C-20 and C-200 carbons.
The more striking observation here is the signal at
136.3 ppm shows correlation with the doublet centered at
8.09–8.11 ppm (8.0 Hz) corresponding to H-10. So the signal
at 136.3 ppm should be due to C-10. Likewise the signal at
121.7 ppm has a cross peak with the doublet in the region
8.34–8.36 ppm (8.0 Hz) which is due to the H-60 proton. Hence
the signal at 121.7 ppm is due to C-60. The signal at 114.3 ppm
has a cross peak with the doublet at 6.96–6.98 ppm (8.0 Hz)
pertaining to H-21 and H-210. So the signal at 114.3 ppm is
due to C-21 and 210 carbon. The signal at 30.7 ppm exhibits
a correlation with the singlet at 2.78 characteristic of CH3 pro-
tons and hence the signal at 30.7 ppm is due to methyl carbon.
It is interesting to note that the signal at 43.0 ppm has a cross
peak with the signal at 4.71 ppm due to the protons of the
hydrazinyl methyene group. Therefore the signal at 43.0 ppm
should be due to the hydrazinyl methyene carbon of the
hydrazine carbothioamide. The signal at 55.7 ppm has a cross
peak with the singlet at 3.89 ppm characteristic of methoxy
protons and hence the signal at 55.7 ppm is assigned to the
methoxy carbon. The HR–Mass spectrum (Fig. S5) of
compound 6 shows (M+H)+ peak at m/z = 460.1332 exact
molecular mass of the compound 6 with its molecular formula
(C25H21N3O4S) is 460.1064. All the other synthesized
compounds (7–10) were characterized similarly and spectral
data were given in the experimental sections.
3. Biological evaluation
3.1. Antimicrobial activity
The antibacterial properties of all the newly synthesized com-
pounds (6–10) were assessed by disk diffusion method [30,31].
The minimum inhibitory concentration (MIC, lg/mL) were
determined in comparison with amikacin and amphotericin.
The in vitro antibacterial activities of the newly synthesized
compounds (6–10) against Escherichia coli and Pseudomonas
aeruginosa are listed in Table 1 for comparison the MIC of
the standard amikacin and amphotericin are also given in
(Table 1).
From Table 1 it is clear that all the compounds except 10
exhibit excellent activity compared to the standard Amphoter-
icin but compound 10 shows almost similar activities to those
of the standard compound. Especially compound 6 having the
coumarinyl moiety was found to be more potent among all andzinyl carbothioamide derivatives (6–10).
MIC (lg/mL)
6 7 8 9 10
1.56 1.56 12.5 25 50
3.12 6.25 6.25 12.5 50
1.56 12.5 12.5 12.5 100
3.12 3.12 12.5 25 50
1.56 1.56 3.12 12.5 100
1.56 3.12 6.25 6.25 50
1.56 6.25 6.25 25 50
3.12 3.12 6.25 6.25 50
1.56 1.56 12.5 12.5 25
446 D. Chinnaraja, R. Rajalakshmiexhibits an enhanced activity than amikacin and amphotericin.
Similarly among the two adamantyl substituted hydrazinyl
carbothioamides (7 and 8), compound 7 shows very good
activity than 8. The decreased activity of compound 8 mayFigure 2 Docking of inhibiting ligand molecules 6–10.
Figure 3 Docking of inhibiting ligand molecules 6–10.
Figure 4 Docking of inhibiting ligand molecules 6–10.be due to the presence of electron releasing methoxy substitu-
ent in the para position of the aryl ring.
Compound 10 having the trimethoxy phenyl ring not only
shows similar activity but also demonstrated a poor activity
against the germs E. coli and P. aeruginosa when compared
to the standard. This also might be due to the presence of three
electron releasing methoxy substituent in the phenyl ring
attached to the N-1 of compound 10.
Compounds 6–10 were screened for their antifungal activity
against Aspergillus ﬂavus and Aspergillus niger. Among the ﬁve
compounds (E)-N-(2-(4-methoxyphenyl)-2-oxoethyl)-2-(1-(2-
oxo-2H–benzo[g]chromen-3-yl) ethylidene) hydrazine carbo-
thioamide) (6) shows excellent activity against the entire tested
organism whereas 7 and 8 show only moderate activity. But 10
shows relatively poor activity against the entire tested microor-
ganism. Keeping in view of the above excellent in vitro antimi-
crobial activities shown by the all the synthesized compounds
(6–10), it is thought worthwhile to carry out docking studies to
investigate their anticancer activity.
3.2. Molecular docking studies
Unique bioactivities of some compounds can be illuminated by
interaction between the compounds and this target protein.Figure 5 Docking of inhibiting ligand molecules 6–10.
Figure 6 Docking of inhibiting ligand molecules 6–10.
Table 2 Molecular docking binding energy of hydrazinyl
carbothioamide derivatives (6–10).
Drug (ligand) Breast cancer
target protein (Receptor)
Binding
energy [kcal/mol]
6 1JNX 8.40
7 7.99
8 6.75
9 5.79
10 5.82
Tamoxifen
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Figure 7 Histogram chart of ligands vs binding energy.
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tial drug-target interaction which plays a vital role in drug
discovery.
Molecular docking studies are performed to ﬁnd essential
active site residues playing role in the activity or selectivity
of the newly synthesized compounds against target protein
(PDB: 1JNX). It also expresses the orientation of the inhibitorsTable 3 Bonded residues, hydrogen bond, bond distance and bond
Compounds Protein [PDB–ID] Bonded residues
6 1JNX Protein:X:LYS1702:HZ2
Ligand:0:H
Ligand:0:H
7 Protein:X:ILE1680:HN
Protein:X:LYS1702:HN
Ligand:0:H
8 Protein: X: LYS1759: HZ3
Ligand:0:H
9 Protein:X:HIS1673:HD1
Ligand:0:H
10 Protein: ILE1680: NH
Protein: X: GLN1779:
HE21
Ligand:0:Hand interaction patterns, which suggest the role of various
functional groups present.
All the ﬁve compounds were chosen for molecular docking
studies using rigid docking method. Auto docking 4.2 [32] was
used to determine the orientation of inhibitors bound in the
active site of the breast cancer target protein (Receptor)
1JNX. Algorithm genetic method, implemented in the pro-
gram AutoDock 4.2 was employed. The docking of inhibiting
ligand molecules 6–10 with the protein 1JNX reveals that all
the inhibitors are in bonding with more than one amino acid
residues and thereby they occupy the active pockets of the
protein 1JNX shown in Figs. 2–6. Theoretically all the ﬁve
inhibitor molecules (6–10) exhibit very good binding energy
as shown in Table 2.
The inhibitor 6 forms three hydrogen bonds with bond dis-
tances 2.179, 2.058 and 2.183 A˚, inhibitor 7 and 10 also form
three hydrogen bonds with the amino acid residues of protein
1JNX. But the ligands 8 and 9 found form only two hydrogen
bonds with the amino acid LYS 1759.
From the histogram (Fig. 7) it is clear that all the inhibitors
are found to possess maximum binding energy than the stan-
dard Tamoxifen (most popular breast cancer drug). All the
newly synthesized compounds are found to be good inhibitors
of the target protein 1JNX. In particular the activity gets
increased even further when a coumarin moiety is introduced
(ligand 6).
Docking studies revealed that the inhibitors (6–10) are
found to be interacting with active site of residues like
LYS 1702: HZ2, ILE1680: HN, LYS1759:HZ3, GLN1779:
HE21. The binding energy of the Tamoxifen (11) the most
popular drug for breast cancer is also given in (Table 2).
The Histogram chart of ligand vs binding energy is given
in Fig. 7.
All the compounds studied were found to form three strong
hydrogen bonds with the protein 1JNX except compound 8
which forms only two strong hydrogen bonds with the receptor
(breast cancer cell target protein) moiety. Bonded residues,
hydrogen bond, bond distance and bond energy are given in
(Table 3 S6).
Among the ﬁve molecules investigated, (E)-N-(2-(4-methoxy-
phenyl)-2-oxoethyl)-2-(1-(2-oxo-2H-benzo[g]chromen-3-yl)eth-
ylidene)hydrazine carbothioamide (6) with the best antibacterial
activity shows a very good binding energy of 8.40 kcal/molenergy (6).
Hydrogen bond Bond distance (A˚) Bond energy [kcal/mol]
3 2.179 0.468
2.058 2.075
2.183 1.758
3 2.154 2.881
2.002 5.558
2.158 4.466
2 2.188 0.001
2.163 0.427
2 1.839 4.887
1.84 1.561
3 2.104 5.250
1.922 5.119
1.912 6.558
448 D. Chinnaraja, R. Rajalakshmiand it may be considered as a good inhibitor of the protein
1JNX.4. Conclusions
We have designed and synthesized new classes of hydrazinyl
carbothioamide derivatives by introducing aryl ethanone into
the N-4 atom of hydrazinyl carbothioamides and their biolog-
ical activities are evaluated. Almost all the compounds dis-
played excellent antimicrobial activities. Molecular docking
studies also revealed that all the compounds (6–10) possess
maximum binding energy than the representative drug Tamox-
ifen and may all be considered as good inhibitors of 1JNX.
One can conclude that these novel ligands are more efﬁcient
drugs for breast cancer than Tamoxifen.
5. Experimental section
5.1. Instruments
The IR spectrum was recorded in an AVATAR-330 FT-IR
spectrophotometer and only noteworthy absorption levels
(reciprocal centimeters) were listed. 1H NMR spectra were
recorded at 400 and 500 MHz on a Bruker AMX 400 and
500 MHz spectrophotometer using CDCl3 as solvent and
TMS as the internal standard. 13C NMR spectra were recorded
at 100 and 125 MHz on a Bruker AMX 400 and 500 MHz
spectrophotometer using CDCl3 as a solvent. HR-Mass
(ESI) was carried out in a Bruker Maxis instrument in the
School of Chemistry, University of Hyderabad. Elemental
analyses (CHN) were recorded on a Thermo Finnigan Flash
EA 1112 analyzer at the School of Chemistry, University of
Hyderabad. Routine monitoring of the reactions was per-
formed by TLC, using silica gel plates (Merck 60 F254) and
compounds were visualized with a UV light at 254 nm.
5.2. General procedure for the synthesis of 3-acetyl-2H-
benzo[g]chromen-2-one
A mixture of 2-hydroxy naphthaldehyde (1) and ethyl acetoac-
etate (2) was prepared. Piperidine was added dropwise to this
mixture while stirring (Scheme 1). The reaction mixture was
left overnight, resulting in the formation of a yellow colored
solid. Puriﬁcation by recrystallization (in EtOH) gave 3-
acetyl-2H-benzo[g]chromen-2-one (3) (85%) as yellow crystal.
5.2.1. 3-acetyl-2H-benzo[g]chromen-2-one (3)
Yellow crystal; yield (85%); m. p 100–102 C; mf C15H10O3;
1H NMR (400 MHz, CDCl3) 2.78 (3H, CH3), 7.42–7.45 (d,
CH, J= 12.0 Hz), 7.58–7.62 (t, CH, J= 16.0 Hz), 7.71–7.75
(t, CH, J= 12.0 Hz), 7.89–7.91 (d, CH, J= 8.0 Hz), 8.06–
8.09 (d, CH, J= 12.0 Hz), 8.30–8.33 (d, CH, J= 12.0 Hz),
9.25 (s, H); IR (KBr); 1643 (C‚O), 1720 (C‚O, coumarine
ring), 3071 (C–H stretching).
5.3. Synthesis of hydrazine carbothioamide derivatives
Equimolar mixture of ketones (or) aldehyde, thiosemicarba-
zide (5) and substituted phenacyl bromide (4) are mixed and
subjected to microwave irradiation for 50–180 s at a heatingof 320 W Scheme 1. After the reaction has completed it is
taken out, the solid product was recrystallized from ethanol
to get pure compounds.
5.3.1. (E)-N-(2-(4-methoxyphenyl)-2-oxoethyl)-2-(1-(2-oxo-
2H-benzo[g]chromen-3-yl)ethylidene)hydrazine carbothioamide
(6)
Pale green solid; yield (78%); m. p 120–122 C; 1H NMR
(400 MHz, CDCl3) 2.80 (s, 3H, CH3), 3.91 (s, 3H, OCH3),
4.72 (s, 2H, CH3) 6.98–7.00 (d, CH, 2H, J= 8.0 Hz), 7.48–
7.50 (d, CH, J= 8.0 Hz), 7.54–7.55 (d, CH, J= 4.0 Hz),
7.62–7.65 (t, CH, J= 12.0 Hz), 8.37–8.39 (d, CH,
J= 8.0 Hz), 8.11–8.13 (d, CH, J= 8.0 Hz), 7.91–7.96 (t,
CH, 2H, J= 16.0 Hz), 7.72–7.79 (m, CH, 2H), 9.33 (s, couma-
rine CH); 13C NMR (100 MHz, CDCl3) 30.3, 42.9, 55.6, 112.8,
114.3, 116.5, 121.7, 122.5, 126.6, 126.9, 129.2, 129.8, 130.9,
136.3, 143.3, 156.2, 159.4, 164.0, 189.1, 195.6; IR (KBr).
1601 (C‚N), 1656 (C‚O), 1315 (C‚S), 3429 (NH); HR-
MS (ESI-MS) Exact M. W. 459.1253; found: 460.1332
(M+H)+; CHN analysis: C25H21N3O4S. Anal. Calcd. (%)
for: C, 65.34; H, 4.61; N, 9.14; found (%): C, 65.39; H, 4.56;
N, 9.29.
5.3.2. (Z)-2-((7aS)-hexahydro-1H-2,6-methanoinden-4(2H)-
ylidene)-N-(2-oxo-2phenylethyl) hydrazine carbothioamide (7)
Pale white solid; yield (71%); m. p 103–105 C; 1H NMR
(400 MHz, CDCl3) 0.84–0.89 (m, 3H, CH2), 1.41–1.42 (d,
CH, 2H, J= 4.0 Hz), 1.64 (s, CH) 1.74 (s, CH) 1.85 (s, CH),
1.92 (s, CH), 1.98–2.01 (t, CH, 2H, J= 12.0 Hz), 2.06–2.09
(d, 2H, J= 12.0 Hz), 2.54 (s, 2H), 7.22 (s), 7.43–7.46 (d,
CH, 2H, J= 12.0 Hz), 8.06–8.08 (d, CH, 2H, J= 8.0 Hz);
13C NMR (100 MHz, CDCl3) 27.4, 36.3, 39.2, 39.4, 43.0,
47.0, 112.2, 114.0, 114.3, 126.9, 130.9, 164.5, 189.2; IR
(KBr). 1601 (C‚N), 1656 (C‚O), 1315 (C‚S), 3429 (NH);
LC-MS m/z: 341; CHN analysis: C19H23N3OS. Anal.Calcd.
(%) for: C, 66.83; H, 6.79; N, 12.31; found (%): C, 66.72; H,
6.76; N, 12.44.
5.3.3. (Z)-2-((7aS)-hexahydro-1H-2,6-methanoinden-4(2H)-
ylidene)-N-(2-(4-methoxyphenyl)-2-oxoethyl)hydrazinecarbot-
hioamide (8)
White solid; yield (69%); m. p 110–112 C; 1H NMR
(400 MHz, CDCl3) 0.87–0.91 (m, 3H, CH2), 1.44–1.47 (d,
CH, 2H, J= 12.0 Hz), 1.66 (s, CH) 1.75 (s, CH) 1.86 (s,
CH), 1.93 (s, CH), 1.97–2.03 (t, CH, 2H, J= 16.0 Hz), 2.07–
2.11 (d, 2H, J= 16.0 Hz), 2.38 (s, 2H), 3.90 (s, 3H, OCH3),
7.46–7.49 (d, CH, 2H, J= 12.0 Hz), 8.19–8.23 (d, CH, 2H,
J= 16.0 Hz); 13C NMR (100 MHz, CDCl3) 27.4, 36.3, 39.6,
39.7, 43.2, 47.4, 55.3, 112.1, 113.0, 114.1, 127.9, 132.5, 163.3,
188.0; IR (KBr); 1597 (C‚N), 1621 (C‚O), 1384 (C‚S),
3421 and 3452 (NH); LC-MS. m/z = 371; CHN analysis:
C20H25N3O2S. Anal. Calcd. (%) for: C, 64.66; H, 6.78; N,
11.31; found (%): C, 64.62; H, 6.75; N, 11.27.
5.3.4. (E)-2-((4-chlorophenyl)(phenyl)methylene)-N-(2-(3,4-
dimethoxyphenyl)-2-oxoethyl)hydrazinyl carbothioamide (9)
Pale yellow solid; yield (73%); m. p 147–149 C; 1H NMR
(400 MHz, CDCl3) 4.72 (s, 2H, CH2), 3.94 (s, 6H, OCH3),
6.81 (s, CH), 6.91–6.96 (m, 3H) 7.35 (s, CH, 2H), 7.48–7.54
(d, CH, 3H, J= 24.0 Hz), 7.59 (s, CH), 7.62–7.63 (d, CH,
J= 4.0 Hz), 7.64–7.65 (d, CH, J= 4.0 Hz); 13C NMR
Design and synthesis of hydrazinyl carbothioamide derivatives 449(100 MHz, CDCl3) 42.7, 56.1, 110.1, 110.3, 110.4, 110.5, 111.2,
123.4, 123.62, 123.6, 124.9, 125., 127.1, 128.3, 149.6, 149.8,
154.7, 155.4, 155.8, 186.0, 189.4; IR (KBr) 1585 (C‚N),
1649 (C‚O), 1399 (C‚S), 3391 (NH); LC-MS. m/z = 468;
CHN analysis: C24H22ClN3O3S. Anal. Calcd. (%) for: C,
61.60; H, 4.74; N, 8.98; found (%): C, 61.57; H, 4.77; N, 8.84.
5.3.5. (E)-N-(2-oxo-2-phenylethyl)-2-(3, 4, 5-
trimethoxybenzylidene)hydrazine carbothioamide (10)
Green solid; yield (77%); m. p 160–162 C; 1H NMR
(400 MHz, CDCl3) 3.89 and 3.97 (d, 9H, (OCH3)3), 4.75 (s,
CH, CH2), 6.98–7.00 (d, CH, 3H, J= 8.0 Hz), 7.17 (s, CH),
7.88–7.91 (d, 2H, J= 12.0 Hz), 7.30 (s, CH) 9.90 (s, N‚CH);
13C NMR (100 MHz, CDCl3) 42.9, 55.6, 56.1, 61.0, 106.7,
112.1, 114.3, 126.9, 130.9, 153.6, 164.8, 189.1; IR (KBr).
1595 (C‚N), 1665 (C‚O), 1327 (C‚S), 2975 and 2928
(NH); LC-MS m/z = 387; CHN analysis: C19H21N3O4S. Ana-
l.Calcd. (%) for: C, 61.77; H, 5.18; N, 11.37 found (%): C,
61.84; H, 5.23; N, 11.26.
5.4. Biological activity
The in vitro activities of the compounds were tested in Sabou-
raud’s dextrose broth (SDB) (Hi–media, Mumbai) for fungi
and Sabouraud’s dextrose agar (SDA) for bacteria by two fold
serial dilution method. The test compounds were dissolved in
dimethylsulfoxide (DMSO) to obtain 1 mg/mL stock solution.
Seeded broth (broth containing microbial spores) was pre-
pared in SDA from 24 objective old bacterial cultures on nutri-
ent agar (Hi-media, Mumbai) at 37 ± 1 C while fungal spores
of 1–7 days old were suspended in SDA. The colony forming
units (cfu) of the seeded broth were determined by the plating
technique and adjusted in the range of 103–107 cfu/mL. The
ﬁnal inoculum six was 107 cfu/mL for antifungal assay. Testing
was performed at pH 8 of the solution of test compound was
added to 1.8 ml of seeded broth to form the ﬁrst dilution.
One milliliter of this was diluted with a further 1 mL of the
seeded broth to give the second dilution and so on till dilutions
of desired volume were obtained. A set of assay tubes contain-
ing only incubated broth was kept as control and likewise sol-
vent controls were also used simultaneously. The tubes were
incubated in BOD incubators at 37 C for bacteria and 28 C
for fungi. Amikacin and amphotericin were used as standards.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.jscs.2014.
10.002.
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